bioAffinity Technologies Selected as Finalist for Cancer Innovation Award
March 06, 2019 11:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, March 06, 2019 (GLOBE NEWSWIRE) -- Healthcare innovators Lyfebulb and Helsinn selected bioAffinity Technologies, a privately held biotech company developing diagnostics and therapeutics...
South Texas Veterans Health Care System Joins Test Validation Trial of bioAffinity’s CyPath® Lung
October 23, 2018 11:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, Oct. 23, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biotech company, today announced that the South Texas Veterans Health Care System (STVHCS), which is...
bioAffinity Licenses CyPath® Lung to Precision Pathology Services
October 10, 2018 12:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, Oct. 10, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biotech company, today announced a licensing agreement with Precision Pathology Services for the continued...
bioAffinity Technologies Welcomes Mohsin Y. Meghji to Board of Directors
July 31, 2018 11:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, July 31, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biomedical company advancing breakthrough cancer diagnostics and therapeutics, is pleased to welcome Mohsin...
bioAffinity Technologies Opens Test Validation Trial of CyPath® Lung
July 17, 2018 14:40 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, July 17, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held cancer diagnostics company, today announced it has commenced its test validation trial for CyPath® Lung, an...